Evidence map›Paper›PMID 35554754›Full record

ArticleInternational journal of clinical oncology2022

Usefulness of dual isotope

Sho Osawa, Masahiko Tosaka, Keishi Horiguchi, Azusa Tokue, Tetsuya Higuchi, Yoshito Tsushima, Yuhei Yoshimoto

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Delayed Uptake onClinical case reports · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sho OsawaDepartment of Neurosurgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Masahiko TosakaDepartment of Neurosurgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. nstosaka@gunma-u.ac.jp.ORCID http://orcid.org/0000-0002-4430-751X
Keishi HoriguchiDepartment of Neurosurgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Azusa TokueDepartment of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Tetsuya HiguchiDepartment of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Yoshito TsushimaDepartment of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Yuhei YoshimotoDepartment of Neurosurgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Gunma University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreoperative differential diagnosis between primary central nervous system lymphoma (PCNSL) and glioblastoma (GBM) is important because these tumors require different surgical strategies. This study investigated the usefulness of dual isotope, iodine-123-labeled N-isopropyl-p-iodo-amphetamine (

methodsTwenty-five PCNSL patients and 27 GBM patients who underwent dual isotope imaging,

resultsDelayed phase

conclusionDelayed phase

Indexed as

Brain NeoplasmsGlioblastomaLymphomaCentral Nervous SystemDiagnosis, DifferentialHumansIodine RadioisotopesRadiopharmaceuticalsThallium RadioisotopesTomography, Emission-Computed, Single-PhotonIodine-123Iodine RadioisotopesRadiopharmaceuticalsThallium-201Thallium Radioisotopes123I-IMP SPECT201Tl SPECTADCGlioblastomaPrimary central nervous system lymphoma

Identifiers

PMID35554754
OpenAlexW4280508918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.